Bill > HB2410

This bill modifies West Virginia's existing right-to-try law by expanding the definition of patients who can access investigational medical treatments. The bill broadens the eligibility criteria from patients with terminal illnesses to those with life-threatening or severely debilitating conditions, and adds a significant new provision allowing patients to access treatments uniquely produced for their individual genetic profile, such as personalized gene therapies and neoantigen vaccines. The bill removes previous restrictions like the requirement to be within 100 miles of a clinical trial and simplifies the definition of eligible patients. The informed consent requirements remain detailed, mandating that patients (or their guardians) understand potential risks, that insurance may not cover the experimental treatment, and that they could be financially responsible for associated medical costs. The bill aims to give patients with serious medical conditions more options for accessing cutting-edge, potentially life-saving medical treatments that have passed initial clinical trials but have not yet received full FDA approval, with a particular focus on personalized medical interventions tailored to an individual's specific genetic makeup.

Health and Social Services, Justice

http://www.wvlegislature.gov/Bill_Status/Bills_history.cfm?input=2410&year=2025&sessiontype=RS&btype=bill